Article and Video CATEGORIES

Cancer Journey

Search By

Patient Education Ambassador Program - Rafeh Naqash MD, Understanding Clinical Trials
dbrock
2020 PEA Program Clinical Trial Series - Naqash - Understanding Clinical Trials
Author
Abdul Rafeh Naqash, MD
Image
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials.

 

For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doctors/fumiko-chino).

In these first videos, Drs. Naqash and Chino and Ms. Elkins discuss:
  1. the phases of clinical trials and what they mean
  2. how medical data will be used and if it would be used without the participant's knowledge
  3. whether clinical trials are only for people who have no other options
  4. eligibility for clinical trials
  5. what a ‘first-in-human' trial means, and whether participants are a ‘guinea pig’

 

#clinicaltrial #genentech #lilly #cancerGRACE

 

 

To join the conversation, visit https://cancergrace.org/forum.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on